The protein kinase maternal and embryonic leucine zipper kinase (MELK) is critical for mitotic progression of cancer cells; however, its mechanisms of action remain largely unknown. By combined approaches of immunoprecipitation/mass spectrometry and peptide library profiling, we identified the eukaryotic translation initiation factor 4B (eIF4B) as a MELK-interacting protein during mitosis and a bona fide substrate of MELK. MELK phosphorylates eIF4B at Ser406, a modification found to be most robust in the mitotic phase of the cell cycle. We further show that the MELKeIF4B signaling axis regulates protein synthesis during mitosis. Specifically, synthesis of myeloid cell leukemia 1 (MCL1), an antiapoptotic protein known to play a role in cancer cell survival during cell division, depends on the function of MELK-elF4B. Inactivation of MELK or eIF4B results in reduced protein synthesis of MCL1, which, in turn, induces apoptotic cell death of cancer cells. Our study thus defines a MELK-eIF4B signaling axis that regulates protein synthesis during mitosis, and consequently influences cancer cell survival.
The protein kinase maternal and embryonic leucine zipper kinase (MELK) is critical for mitotic progression of cancer cells; however, its mechanisms of action remain largely unknown. By combined approaches of immunoprecipitation/mass spectrometry and peptide library profiling, we identified the eukaryotic translation initiation factor 4B (eIF4B) as a MELK-interacting protein during mitosis and a bona fide substrate of MELK. MELK phosphorylates eIF4B at Ser406, a modification found to be most robust in the mitotic phase of the cell cycle. We further show that the MELKeIF4B signaling axis regulates protein synthesis during mitosis. Specifically, synthesis of myeloid cell leukemia 1 (MCL1), an antiapoptotic protein known to play a role in cancer cell survival during cell division, depends on the function of MELK-elF4B. Inactivation of MELK or eIF4B results in reduced protein synthesis of MCL1, which, in turn, induces apoptotic cell death of cancer cells. Our study thus defines a MELK-eIF4B signaling axis that regulates protein synthesis during mitosis, and consequently influences cancer cell survival.
MELK | eIF4B | MCL1 | protein synthesis | mitosis M aternal and embryonic leucine zipper kinase (MELK) is a serine/threonine kinase with potential roles in mitosis. Similar to other established mitotic factors, such as Aurora kinases and cyclin B1, MELK demonstrates increased protein abundance during mitosis and is degraded when cells progress into G1 phase (1, 2) . Our recent study proposed an essential role of MELK in the mitotic progression of specific cancer cell types, with MELK knockdown resulting in multiple mitotic defects, including G2/M arrest and mitotic cell death (2) . Despite these advances, there is a lack of mechanistic understanding of the role of MELK during cell division. An immediate question is the identity of the MELK substrates that mediate its role in mitosis, such as promoting mitotic cell survival.
Myeloid cell leukemia 1 (MCL1) is an important negative regulator of apoptosis. Uniquely among the Bcl-2 family, it is turned over rapidly by ubiquitin-mediated proteolysis and must be continuously resupplied by translation (3, 4) . Protein abundance of MCL1 decreases during prolonged mitotic arrest induced by antimicrotubule drugs, rendering arrested cells highly sensitive to inhibitors of other Bcl-2 family members (5) . We thus speculate that synthesis of MCL1 is important for cell survival during normal and drug-arrested mitosis and, conversely, that a drug that decreases MCL1 synthesis during mitosis might have anticancer potential.
The rate of protein synthesis and other basic biological processes, such as DNA or RNA biogenesis, fluctuates throughout the cell cycle. Overall protein synthesis significantly decreases when cells enter mitosis (6, 7) , consistent with the notion that macromolecule synthesis predominantly occurs in interphase before the segregation of cellular mass in mitosis.
A recent study based on ribosome profiling identified a set of genes that are translationally repressed in mitosis, and proposed that suppressed protein synthesis might provide a unique mechanism to complement the posttranslational inactivation of specific proteins (8) . Nevertheless, protein synthesis still occurs during mitosis, although at an overall rate that is 30-65% of the overall rate in interphase cells (6, 8, 9) . Moreover, the translation of certain mRNAs, such as c-Myc, MCL1, and ornithine decarboxylase (ODC), is even elevated during mitosis (8, 9) . Together, these studies suggest that protein synthesis may be functionally important for mitotic cells and might be finely regulated by as yet unidentified signaling pathways.
In this study, we aimed to identify downstream effectors of the mitotic kinase MELK. Intriguingly, we found that MELK phosphorylates the eukaryotic translation initiation factor 4B (eIF4B). Our data implicate the MELK-eIF4B pathway as a previously unrecognized signaling mechanism regulating mitotic protein synthesis and tumor cell survival.
Results
Peptide Library Screen Identifies the Optimal Substrate Motif for MELK. To identify kinase substrates of MELK that mediate its role in the regulation of mitosis and cell survival, we determined the consensus phosphorylation motif for MELK. Proteins carrying the optimal substrate motif are likely phosphorylated by MELK, and thus represent potential in vivo substrates. We expressed active full-length human MELK in insect cells and subjected the purified kinase to positional scanning peptide library screening, a technique that has been used extensively to identify optimal substrate motifs for kinases (10, 11) . The profiling demonstrated that MELK is highly selective for its substrate, with a strong preference for arginine at the −3 position relative to the phosphoacceptor
Significance
The work identifies the eukaryotic translation initiation factor 4B (eIF4B) as a substrate of maternal and embryonic leucine zipper kinase (MELK), a mitotic kinase known to be essential for aggressive types of malignancy. The MELK-eIF4B axis thus represents a previously unidentified signaling pathway that regulates protein synthesis during mitosis and, consequently, the survival of cancer cells.
site (Fig. 1A) . In addition, arginine was positively selected in the −2 and −4 positions, and hydrophobic residues were strongly selected against in the −3 position (Fig. 1A) .
Because bioinformatics analysis revealed a large number of proteins carrying the optimal motif, we sought another approach to narrow down the hits. We reasoned that proteins that physically interact with MELK during mitosis might represent potential substrates. To identify such proteins, we stably introduced doxycycline-inducible Flag-tagged MELK into the breast cancer cell line MDA-MB-468 and immunoprecipitated Flag-MELK from lysates of mitotic cells obtained by nocodazole-induced cell cycle arrest at prometaphase. Tandem mass spectrometric analysis identified high enrichment of MELK together with eIF4B ( Fig. 1B and Table S1 ), a translation initiation factor with roles in regulating cell survival (12) . The MELK-eIF4B interaction was further confirmed by ectopic expression of MELK or eIF4B in HEK293T cells (Fig. S1A) .
We proceeded to examine whether eIF4B carries the optimal substrate motif for MELK. Two serine residues of eIF4B, Ser406 and Ser422, conformed to the consensus phosphorylation sequence ( Fig. 1C and Fig. S1B ). In addition, S406/S422 and their flanking residues are evolutionarily conserved across vertebrates ( Fig. 1C and Fig. S1B ), indicating that these residues might be subject to posttranslational modifications. Together, these findings suggest that eIF4B might be a protein substrate of MELK.
EIF4B Phosphorylation During Mitosis. Given that MELK is a mitotic kinase, its potential role in regulating eIF4B phosphorylation drove us to investigate first how eIF4B phosphorylation occurs at different stages of the cell cycle. We harvested mitotic MDA-MB-468 cells at prometaphase through nocodazole-or paclitaxel-induced cell cycle arrest. As expected, the cells were enriched for mitotic factors, including MELK, cyclin B1, and Aurora kinase A, and, interestingly, exhibited strong phosphorylation of eIF4B at Ser406, but not at Ser422 (Fig. 1D and Fig. S1C ). In contrast, phosphorylation of some of the known upstream signaling molecules, such as Akt or MAPK (13) , was apparently decreased in mitotic cells ( Fig. 1D and Fig. S1C ).
MELK Directly Phosphorylates eIF4B at Ser406. To investigate whether MELK phosphorylates eIF4B, we first performed in vitro kinase assays using purified recombinant MELK and eIF4B. MELK potently induced phosphorylation of eIF4B at Ser406, and to a lesser extent at Ser422, as indicated by immunoblot analysis with phospho-specific antibodies ( Fig. 2A) . We also examined the effect of chemical inhibition of MELK kinase activity using OTSSP167 (14) , and found that the inhibitor efficiently suppressed MELK-driven eIF4B phosphorylation at Ser406 in a dose-dependent manner ( Fig. 2A) . To confirm that MELK is a bona fide kinase for eIF4B, we performed kinase reactions consisting of MELK (full-length or kinase domain) together with eIF4B (wild type or with mutations introduced at Ser406 or Ser422). The immunoprecipitated eIF4B was readily phosphorylated at Ser406 by full-length MELK or its kinase domain (Fig. 2B) , and, as expected, the phosphorylation was abolished when serine was mutated to alanine (S406A) (Fig. 2B) . In contrast, MELK was unable to catalyze the phosphorylation of eIF4B at S422 (Fig. S2A) .
To test whether eIF4B phosphorylation in mitotic cells is regulated by MELK, we used a doxycycline-inducible shRNA platform to knock down MELK expression (15) and found that Ser406 phosphorylation of eIF4B in mitotic cells (MDA-MB-468, BT549) was strongly suppressed by the loss of MELK (Fig.  2C and Fig. S2B ). Moreover, the MELK inhibitor OTSSP167 reduced eIF4B phosphorylation in mitotic cells at concentrations in the nanomolar range. Interestingly, OTSSP167 concurrently increased the electrophoretic mobility of MELK ( Fig. 2D and Fig. S2C ), suggesting possible dephosphorylation and inactivation of MELK. Together, data from in vitro and in vivo assays point to a predominant role of MELK in phosphorylating eIF4B at Ser406 in mitotic cells.
Both MELK expression and eIF4B phosphorylation, although most abundant during mitosis, were also observed in interphase, such as in cells in G1 phase (Fig. 1D ), suggesting that MELK might also contribute to eIF4B phosphorylation outside of mitosis. Indeed, MELK inhibition in asynchronized cells (MDA-MB-468 and MDA-MB-231) caused a significant, albeit reduced, inhibition of eIF4B phosphorylation (Fig. S2D ). In addition, treatment of mice bearing xenografted MDA-MB-231 tumors with OTSSP167 resulted in reduced phosphorylation of eIF4B at Ser406 in the absence of suppressed Akt/MAPK signaling (Fig.  2E ). These observations indicate that the role of MELK in phosphorylating eIF4B is most prominent in mitosis but might extend to other cell cycle stages. 
Chemical Library Screen Identifies MELK as the Unique Mitotic Kinase
Phosphorylating eIF4B. We next investigated whether MELK is the only kinase responsible for eIF4B phosphorylation during mitosis. A large number of kinases are expressed in mitotic cells, including Aurora kinases, CDK1, MPS1, and PLK1. Recent studies also documented hyperactivation of mTOR complex 1 during mitosis despite the fact that the protein abundance of mTOR does not fluctuate during the cell cycle, unlike the established mitotic kinases (7). We first tested whether inhibition of Aurora kinases affects eIF4B phosphorylation. Both MLN8045 and VX-680 (16, 17) suppressed the autophosphorylation of Aurora A and Aurora B (at a high dose for MLN8045) but failed to decrease, and in fact even enhanced, eIF4B phosphorylation ( Fig. 3 A and B) . Similarly, the highly potent ATP-competitive inhibitor of mTOR Torin 1 (18) was also unable to inhibit eIF4B phosphorylation (Fig. 3C ).
To study systemically whether other kinases besides MELK are involved in regulating mitotic phosphorylation of eIF4B, we screened a chemical library for any compounds capable of suppressing eIF4B signaling. The Library of Integrated NetworkBased Cellular Signatures (LINCS) project has collected and characterized more than 200 kinase inhibitors, most of which are commercially available (https://lincs.hms.harvard.edu/). We screened this panel at a single dose of 5 μM by incubation with nocodazole-arrested mitotic cells (MDA-MB-231) for 30 min, followed by immunoblot analysis of phospho-eIF4B (Ser406) (Fig. 3D) . Of the 227 kinase inhibitors tested, only OTSSP167 showed robust inhibition of mitotic eIF4B phosphorylation at Ser406 (Fig. 3E and Table S2 ). Therefore, we concluded that MELK inhibition uniquely induced potent inhibition of mitotic phosphorylation of eIF4B.
A MELK-eIF4B Axis in Mitotic Cells. MELK was recently implicated in the proliferation and survival of basal breast cancer (BBC) rather than luminal breast cancer cells, with MELK depletion causing mitotic errors and mitosis-associated cell death (2). We therefore examined whether eIF4B phosphorylation represents a major downstream event in cell proliferation and survival. Similar to the effect of loss of MELK expression (2), doxycyclineinduced EIF4B knockdown induced apoptotic cell death and the appearance of G2/M markers, such as Aurora A (Fig. 4A and Fig. S3A) ; furthermore, EIF4B knockdown strongly impaired the proliferation of MDA-MB-468 BBC cells (Fig. 4B) .
We then proceeded to investigate whether eIF4B phosphorylation at S406 is critical for the role of MELK or eIF4B in cell proliferation and survival. For this purpose, we introduced doxycycline-inducible 
MELK-eIF4B Signaling Controls Protein Synthesis During Mitosis.
EIF4B is known to stimulate the RNA helicase activity of eIF4A responsible for unwinding the secondary structure of the 5′-UTR of mRNA (19) . In addition, eIF4B promotes protein synthesis, in part, by interacting with eIF3 to facilitate the binding of mRNA with ribosomes (20) . We found that mutating serine 406 to alanine (S406A) strongly decreased the interaction between eIF4B and eIF3 ( Fig. 4E ) and that MELK overexpression promoted S406 phosphorylation as well as the eIF4B-eIF3 interaction (Fig.  S3E ). These data suggest that MELK-mediated eIF4B phosphorylation might be important for efficient formation of the translation initiation complex.
To investigate a potential role of the MELK-eIF4B pathway in mRNA translation during mitosis, we harvested nocodazolearrested mitotic cells (MDA-MB-468) that were pretreated with doxycycline to induce depletion of MELK or eIF4B and detected the synthesis of nascent protein using a puromycin-based approach (21) . We confirmed active protein synthesis in mitotic cells (Fig. S3F ) and found that MELK or EIF4B knockdown strongly reduced the synthesis of nascent proteins (Fig. S3G) . MELK knockdown also resulted in a more than twofold decrease in global protein synthesis, as indicated by the incorporation of a methionine analog into nascent protein (Fig. 4F) . Together, these data suggest a role of MELK-eIF4B signaling in regulating protein synthesis during mitosis.
MELK-eIF4B Regulates MCL1 Protein Abundance and Cancer Cell
Survival. The role of MELK-eIF4B in regulating cell survival during passage through mitosis (Fig. 4 A and B and Fig. S3A ) led us to hypothesize that the synthesis of certain antiapoptotic protein(s) might be highly dependent on MELK-eIF4B signaling. To identify such factor(s), we analyzed the abundance of antiapoptotic proteins in mitotic cells depleted for eIF4B and found that the protein abundance of MCL1 and XIAP, but not Bcl2, Bcl-xL, or BIRC5/ survivin, was reduced upon EIF4B knockdown (Fig. 5A and Fig.  S4A ). This finding is consistent with the faster turnover of MCL1 compared with other BH3 family proteins described previously (3). Also consistent with previous studies (4), active protein synthesis and degradation of MCL1, but not XIAP, were observed in mitotic cells (Fig. 5B and Fig. S4B ). Therefore, we focused on the role of MCL1 in mediating MELK-eIF4B signaling and regulating cell survival.
Similar to eIF4B depletion, MELK knockdown significantly decreased the abundance of MCL1 in mitotic cells (Fig. 5C ). To test whether MCL1 loss promoted by the loss of eIF4B and MELK was caused by an increase in proteolysis or a decrease in synthesis, we added cycloheximide to block mRNA translation and performed immunoblotting to measure protein stability during mitotic arrest. We found that the protein stability of MCL1 was not altered by MELK or eIF4B inhibition (Fig. 5D and Fig. S4C ), indicating that loss of eIF4B and MELK affects MCL1 synthesis but not proteolysis. We next measured mRNA levels of MCL1 using two independent probes for quantitative PCR and found that mRNA expression was not reduced, or was even slightly increased, upon MELK or EIF4B knockdown (Fig. 5E ). To address a direct role of MELK in regulating MCL1 synthesis, we pretreated cells with cycloheximide to deplete MCL1 protein and, after washing away the cycloheximide, treated the cells with MG132 to observe newly synthesized MCL1. MELK inhibition by OTSSP167 efficiently decreased the synthesis of MCL1 protein (Fig. 5F ), suggesting a role of MELK in regulating the de novo synthesis of MCL1, presumably via regulation of eIF4B phosphorylation.
To study whether MCL1 synthesis represents a critical downstream effector of the MELK-eIF4B pathway, we introduced exogenous MCL1 into cells stably transduced with tet-on-short hairpin MELK. MCL1 overexpression in MDA-MB-468 cells partially rescued the growth inhibition and cell death resulting from MELK knockdown (Fig. 5 G and H) . We previously found that MELK is selectively required by BBC, an aggressive and therapeutically recalcitrant type of breast cancer (2) . Interestingly, the level of MCL1 transcript was higher in BBC than in other subtypes of breast cancer (Fig. 5I) . Moreover, MCL1 inhibition using a small-molecule inhibitor, MIM1 (22) , caused more prominent defects in cell proliferation in BBC cells than in luminal breast cancer cells (Fig. 5J ). These observations suggest that BBC cells might be addicted to high MCL1 levels for successful passage through mitosis, which, in turn, depends on up-regulation of MCL1 synthesis during mitosis by MELKeIF4B signaling.
Discussion
The cellular functions and regulatory mechanisms of mitotic translation are poorly understood. The Ser/Thr kinase MELK is one of the proteins that show increased abundance during mitosis. Our initial biochemical studies identified eIF4B as one of the kinase substrates of MELK, with selective phosphorylation at Ser406. A chemical library screen of more than 200 kinase inhibitors indicated that MELK is uniquely capable of phosphorylating MELK. We further demonstrated that the MELK-eIF4B signaling pathway regulates protein synthesis in mitotic cells and, in particular, synthesis of the antiapoptotic protein MCL1.
The control of protein synthesis plays a critical role in regulating cell growth, survival, and tumorigenesis (23) . Aberrations in translational control frequently occur in cancer, often through activation of PI3K-MAPK-mTOR signaling (23, 24) but also through overexpression of translation initiation factors, such as eIF4E (25) and helicase protein DHX29 (26) . Here, we identify the MELK-eIF4B pathway as a previously unidentified strategy used by tumor cells to regulate mitotic translation and promote survival. Given the widespread overexpression of MELK in highgrade tumors, our findings in breast cancer may be applicable to many other aggressive types of malignancy, such as high-grade serous ovarian cancer and glioblastoma.
How does eIF4B phosphorylation affect protein synthesis? Consistent with a recent study (27) , we find that eIF4B phosphorylation at Ser406 is required for the interaction between eIF4B and the eIF3 translation initiation complex. Those observations suggest a model in which eIF4B phosphorylation promotes the recruitment of ribosomes to mRNA and, consequently, protein synthesis. Intriguingly, the same eIF4B phosphorylation suppresses neuronal protein synthesis because eIF4B binds to regulatory nonprotein-coding brain cytoplasmic RNAs with high affinity, and is thus sequestered from initiating translation of other proteincoding transcripts (28) . It will be extremely interesting to study how eIF4B phosphorylation regulates protein synthesis in different cell types. Our work demonstrates a role of the MELK-eIF4B pathway in controlling the translation of MCL1, a short-lived antiapoptotic protein whose gene is frequently amplified in various tumor types (29) . Notably, MCL1 gene amplification is observed in breast tumors treated with neoadjuvant chemotherapy (30) . The identified mechanism for regulation of MCL1 synthesis also implicates the MELK-eIF4B pathway as a promising therapeutic target for cancers that display MCL1 gene amplification/overexpression and depend on MCL1 for cell survival.
As the only unstable antiapoptotic BH3 family protein, MCL1 plays a major role in determining the response of cancer cells to therapeutic intervention. Protein degradation of MCL1 is induced during prolonged mitotic arrest promoted by antimicrotubule drugs, such as paclitaxel (5), and it was proposed that sensitivity to this class of drugs depends, in part, on expression levels of the E3 ligases that promote MCL1 ubiquitination (4) . Here, we show that a decrease in MCL1 synthesis also accounts for the selective killing of BBC cells by MELK inhibition. It is not clear why BBC cells are more sensitive to loss of MCL1 synthesis in mitosis than other breast cancer subtypes, although because BBC cells express more MCL1, they may be more addicted to its antiapoptotic effects. Given that the antiapoptotic roles of MCL1 are targeted by multiple modes of chemotherapy, our findings suggest clinical benefits of combination regimens using MELK inhibitors to repress mitotic phosphorylation of eIF4B and consequent MCL1 synthesis.
Although we find that the translation of MCL1 mRNA in mitotic cells is regulated by the MELK-eIF4B pathway, MCL1 overexpression only partially rescued the growth inhibition resulting from the loss of MELK. It is likely that the signaling may also have an impact on the protein synthesis of other prosurvival mRNAs, especially those prosurvival mRNAs with a structured 5′-UTR that consequently have a high dependence on eIF4B (12) . The translation of these mRNAs, including MCL1, may collectively mediate the MELK-eIF4B signaling and regulate the mitotic survival of cancer cells.
Materials and Methods
Cell lines were cultured under standard conditions. Floating mitotic cells were harvested through nocodazole-or paclitaxel-induced metaphase arrest. Both MCL1 and eIF4B were cloned from cDNA libraries prepared from human BCC culture. Protein extraction, immunoblotting, and quantitative RT-PCR were performed using standard methods. A detailed description of reagents and protocols used in this study can be found in SI Materials and Methods.
